Sera Prognostics’ PreTRM Test Cuts NICU Admissions by 22% in First-Time Pregnancies
SERA•Sera Prognostics’ PreTRM test-guided care in 1,783 first-time pregnancies reduced NICU admissions by 22% overall and halved admissions following spontaneous preterm birth, while lowering severe composite morbidity from 9.1% to 6.4%. A number-needed-to-screen of 28 suggests potential healthcare savings and improved neonatal outcomes.
1. Trial Results
In a subgroup of 1,783 nulliparous participants from the PRIME randomized trial, PreTRM test-guided care reduced NICU admissions by 22% overall and achieved a twofold reduction in admissions after spontaneous preterm birth. Severe composite morbidity declined from 9.1% in the control arm to 6.4% in the PreTRM-guided arm.
2. Screening Efficiency
The analysis determined a number-needed-to-screen of 28 first-time pregnancies to prevent one NICU admission, underscoring the test’s screening efficiency in a population lacking prior obstetric history.
3. Clinical Impact
Early risk stratification using the PreTRM biomarker panel enabled timely interventions—such as progesterone, low-dose aspirin, and care management—leading to healthier newborn outcomes in a traditionally underserved first-time mother cohort.
4. Commercial and Cost Implications
By targeting one of the most expensive types of hospital care, the reduction in NICU admissions has the potential to generate meaningful cost savings and support broader payer and provider adoption of the PreTRM pathway.
